Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Drug development stories

Nov 16, 2026

Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push

Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to expand development of treatments for rare blood cancers known as myeloproliferative neoplasms, its 14th or 15th acquisition of 2026.

Nov 16, 2026·3 sources
00
Nov 15, 2026

J&J in talks to acquire eye disease biotech for up to $3.4bn

Johnson & Johnson is poised to acquire a privately held eye disease drug developer in a deal valued at up to $3.4 billion, according to the Financial Times.

Nov 15, 2026·2 sources
00

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sources
00
Nov 13, 2026

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Swiss immune drug developer Windward Bio raised $175 million in its IPO, the biotech sector's 30th listing of the year, to advance lung disease drugs licensed from China.

Nov 13, 2026·2 sources
00
Nov 11, 2026

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.

Nov 11, 2026·3 sources
00

Amgen's Sjögren's drug cuts disease activity in trial

Amgen reported positive trial results showing its experimental drug reduced disease activity in patients with Sjögren's syndrome, a chronic autoimmune condition with limited treatment options.

Nov 11, 2026·2 sources
00
Nov 5, 2026

Alethio Therapeutics raises $90M Series A for rare blood cancer antibody

Oxford spinout Alethio Therapeutics secured $90 million in Series A funding to advance an antibody treatment for myeloproliferative neoplasms, a group of rare blood cancers.

Nov 5, 2026·2 sources
00

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.

Nov 5, 2026·2 sources
00
Nov 4, 2026

Sino Biopharmaceutical signs cancer deal worth up to $7 billion with Boehringer Ingelheim

Sino Biopharmaceutical entered an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate up to approximately $7 billion in total value.

Nov 4, 2026·3 sources
00
Nov 3, 2026

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Servier's sevasemten, acquired from Edgewise for $1.55 billion upfront in June 2026, failed its pivotal trial for muscular dystrophy just five months after the acquisition.

Nov 3, 2026·2 sources
00
Nov 2, 2026

Fresenius signs biosimilars development agreement with WuXi Biologics

German healthcare company Fresenius has entered a partnership with China's WuXi Biologics to develop a pipeline of biosimilar drugs, expanding its presence in the biologics market.

Nov 2, 2026·3 sources
00
Nov 1, 2026

Setara Biosciences launches with $90M for rare disease drug development

Setara Biosciences has started operations with $90 million in funding and a lead drug candidate already in clinical trials for Charcot-Marie-Tooth disease type 2C and overactive bladder.

Nov 1, 2026·4 sources
00
Oct 30, 2026

AbbVie raises annual profit forecast on strong immunology drug sales

AbbVie raised its full-year profit forecast after beating third-quarter expectations, driven by strong demand for its newer immunology and neuroscience drugs as the company navigates the Humira patent cliff.

Oct 30, 2026·2 sources
00

Norrin treatment prevents vision loss in diabetic rats, study finds

Research shows that treatment with norrin helps maintain healthy blood vessels in the retina and preserves vision in diabetic rats, offering potential hope for treating diabetic retinopathy, a complication affecting over 100 million people in the U.S.

Oct 30, 2026·2 sources
00

Blocking microRNA-31-5p interaction reverses heart scarring and atrial fibrillation in study

Researchers at Baylor College of Medicine and University of Oxford found that blocking a specific molecular interaction between microRNA-31-5p and calcitonin receptor reduced atrial fibrosis and abnormal heart rhythms in mouse models and human cells, offering a potential RNA-based therapeutic strategy for atrial fibrillation.

Oct 30, 2026·2 sources
00

FDA advisory committee reviews SYD-101 atropine eye drops for pediatric myopia

An FDA advisory committee convened on October 30 to discuss SYD-101, a low-dose atropine eye drop for slowing pediatric myopia that the FDA declined to approve last year. The treatment met its primary endpoint in a phase 3 trial, but the FDA determined the overall results were insufficient for approval.

Oct 30, 2026·1 source
00
Oct 29, 2026

METTL13 enzyme found to fuel cancer growth by boosting KRAS protein production

Researchers at MD Anderson Cancer Center discovered that the METTL13 enzyme modifies translation machinery to selectively enhance production of cancer-driving proteins like KRAS, offering a potential new therapeutic target upstream of existing KRAS-targeted drugs that face resistance issues.

Oct 29, 2026·3 sources
00

Dren Bio raises $350 million for blood cancer drug ahead of potential 2027 launch

California biotech Dren Bio secured $350 million in funding to advance its lead blood cancer therapy toward a potential market launch by the end of 2027.

Oct 29, 2026·3 sources
00

University of Eastern Finland identifies vitamin transporter protein for brain drug delivery

Researchers at the University of Eastern Finland have identified the SMVT transporter protein that can improve creatine delivery to the brain and potentially enable new therapies targeting the central nervous system. The discovery addresses one of medicine's greatest challenges: delivering drugs across the blood-brain barrier.

Oct 29, 2026·4 sources
00

KAIST researchers develop GB2Ab antibody to treat cancer cachexia in mice

A research team at KAIST has developed GB2Ab, a therapeutic antibody candidate that blocks signals responsible for appetite suppression, weight loss, and muscle wasting in cancer cachexia. The antibody successfully reversed weight and muscle loss in mouse models.

Oct 29, 2026·2 sources
00
Oct 28, 2026

Genmab's petosemtamab cuts death risk by half in head and neck cancer trial

Danish drugmaker Genmab reported its experimental drug petosemtamab reduced the risk of death by 50% in a late-stage study of patients with head and neck cancer, sending US-traded shares up 28%.

Oct 28, 2026·3 sources
00

SAR402663 gene therapy shows 97% reduction in treatment burden for wet AMD in phase 2 trial

A phase 2 study presented in Vienna showed that SAR402663, a single intravitreal gene therapy injection for wet age-related macular degeneration, achieved a 97% reduction in treatment burden with positive efficacy and safety results. More than 90% of patients responded to the medium dose treatment.

Oct 28, 2026·2 sources
00

Formation raises $600 million to accelerate AI drug development

AI biotech startup Formation Bio raised $600 million to acquire or license stalled drug candidates and use AI to accelerate clinical trials, addressing what it sees as the real bottleneck in drug development.

Oct 28, 2026·2 sources
00

WHO releases target regimen profiles for long-acting injectable tuberculosis treatments

The World Health Organization has published target regimen profiles for long-acting injectables (LAIs) for tuberculosis prevention and treatment, aiming to address adherence challenges associated with current daily oral regimens that must be taken over months.

Oct 28, 2026·1 source
00
Oct 27, 2026

Novartis raises profit guidance despite $1.9 billion drug trial setback

Novartis increased its full-year core profit outlook for the third time in 2026, driven by growth of new medicines, but took a $1.9 billion write-down for neuromuscular drug candidate del-desiran following trial failure.

Oct 27, 2026·2 sources
00
Oct 26, 2026

Merck drug extends survival in endometrial cancer, wins FDA priority review

Merck's experimental antibody-drug conjugate reduced death risk by one-third in advanced endometrial cancer patients and received FDA priority review based on late-stage trial data.

Oct 26, 2026·3 sources
00

GSK to nearly double cancer drugs in clinical trials by 2027

GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, according to a Wall Street Journal interview with a company scientist. The expansion follows a dealmaking spree as the British drugmaker accelerates its return to oncology.

Oct 26, 2026·5 sources
00

Bayer wins China approval for stroke prevention drug asundexian

China's drug regulator approved Bayer's blood thinner asundexian for stroke prevention, marking the first approval globally for this new class of anticoagulant. The approval followed a priority review and represents a significant boost for Bayer's pharmaceutical pipeline.

Oct 26, 2026·3 sources
00
Oct 23, 2026

Tegoprubart outperforms tacrolimus in preserving kidney function after transplant, BESTOW trial finds

The Phase 2 BESTOW clinical trial demonstrated that tegoprubart, a novel anti-CD40L antibody therapy, was superior to tacrolimus, the current standard of care, at preserving kidney function in adults receiving their first kidney transplant. The trial results suggest a potential advancement in immunosuppressive treatment regimens for transplant patients.

Oct 23, 2026·3 sources
00

Three drugs show sustained kidney function benefits in IgA nephropathy trials at 2 years

Atacicept, telitacicept, and sibeprenlimab demonstrated unprecedented benefits in stabilizing kidney function in phase 3 trials for IgA nephropathy, with sustained effects at two years.

Oct 23, 2026·2 sources
00

Novartis multiple sclerosis drug remibrutinib shows weaker-than-expected relapse reduction

Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.

Oct 23, 2026·4 sources
00

Pathos AI raises $237M led by Bristol Myers Squibb, partners on Alzheimer's drug development

AI drug development company Pathos AI announced a $237 million Series E funding round led by Bristol Myers Squibb, reaching a $3 billion valuation. The deal includes a collaboration between Pathos AI, Bristol Myers Squibb, and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders.

Oct 23, 2026·4 sources
00

Bristol Myers Squibb and SystImmune breast cancer drug reduces disease progression risk by 59% in phase 3 trial

Bristol Myers Squibb and partner SystImmune announced that their experimental breast cancer treatment izalontamab brengitecan reduced the risk of disease progression or death by 59% compared to standard chemotherapy in patients with advanced HR+/HER2- breast cancer in the phase 3 PANKU-Breast01 study. The late-breaking results are being presented at ESMO 2026.

Oct 23, 2026·4 sources
00

Novartis breast cancer drug Kisqali cuts death risk by 19% after six years in early-stage trial

Novartis reported that its drug Kisqali helped extend survival for women with high-risk, early-stage breast cancer, cutting their risk of death by 19% after six years in trial data.

Oct 23, 2026·2 sources
00

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Tango Therapeutics reported an 82% tumor response rate in a clinical trial combining targeted drugs for advanced pancreatic cancer, presented at ESMO congress.

Oct 23, 2026·2 sources
00

Roche licenses Zymeworks' experimental lung cancer drug ZW209 in deal worth up to $813 million

Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.

Oct 23, 2026·5 sources
00

Johnson & Johnson prostate cancer drug JNJ-6143 shows tumor shrinkage in early-stage trial

Johnson & Johnson reported promising results from an early-stage clinical trial of its experimental oral prostate cancer treatment JNJ-6143, with 77% of patients with advanced prostate cancer experiencing significant drops in PSA levels after treatment. The trial involved patients who had undergone multiple prior treatments.

Oct 23, 2026·4 sources
00

Star Therapeutics raises $200 million to advance pipeline after spinout successes

Star Therapeutics has secured $200 million in private financing to advance its preclinical programs into clinical trials and expand its pipeline. The funding follows the company's successful track record of spinning out companies including Vega and Electra, with Incyte acquiring one of its spinouts in July 2026.

Oct 23, 2026·5 sources
00
Oct 22, 2026

Gilead acquires PepStar inflammation drug program for $1.28 billion

Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental IL-23 receptor inhibitor for inflammatory bowel disease, for $1.28 billion upfront in a deal that could compete with Johnson & Johnson's new immunology pill.

Oct 22, 2026·3 sources
00

Molecular glue RPT04402 stabilizes PP2A protein to inhibit lung and uterine cancer development

Researchers have developed RPT04402, a molecular glue that stabilizes protein phosphatase 2A (PP2A), a key regulator of cell signaling pathways frequently disrupted in tumors. The compound shows promise in inhibiting non-small cell lung cancer and uterine cancer development.

Oct 22, 2026·3 sources
00

UCLA researchers develop MAESTRO AI platform to identify cancer drug combinations

UCLA investigators have created MAESTRO, an artificial intelligence platform that uses large language models to analyze scientific knowledge and identify promising drug combinations to overcome treatment resistance in cancer. The platform was described in the journal Advanced Science.

Oct 22, 2026·2 sources
00

FDA approves dolutegravir HIV drug for newborns based on international clinical trial

The U.S. Food and Drug Administration has approved dolutegravir, a second-generation antiretroviral drug, for use in newborns exposed to HIV-1. The approval was informed by an international phase 1 study conducted through the IMPAACT Network that established safe and effective dosing regimens for full-term neonates.

Oct 22, 2026·3 sources
00
Oct 21, 2026

Roivant's brepocitinib succeeds in phase 3 trials for non-infectious uveitis

Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.

Oct 21, 2026·7 sources
00
Oct 20, 2026

Rapport Therapeutics' RAP-219 meets primary endpoint in phase 2 bipolar mania trial

Rapport Therapeutics announced positive phase 2 results for RAP-219, an oral AMPA receptor modulator licensed from Johnson & Johnson, showing improvement in bipolar mania symptoms. This marks the company's second phase 2 success for the asset in 14 months.

Oct 20, 2026·3 sources
00

Lycia Therapeutics targets $938 million valuation in US IPO

Drug developer Lycia Therapeutics announced it is targeting a valuation of up to $937.7 million in its U.S. initial public offering, joining other biotech companies entering the IPO market.

Oct 20, 2026·3 sources
00
Oct 19, 2026

Mirikizumab achieves clinical remission in pediatric ulcerative colitis phase 3 trial

Eli Lilly's mirikizumab (Omvoh) achieved clinical and endoscopic remission rates in children with ulcerative colitis that exceeded historical adult placebo outcomes at week 12 in the SHINE-2 phase 3 study. The positive pediatric data could provide a competitive advantage for the IL-23p19 inhibitor in the inflammatory bowel disease market.

Oct 19, 2026·3 sources
00

Merck KGaA acquires Silence Therapeutics for $1.3 billion

German drugmaker Merck KGaA will acquire UK-based Silence Therapeutics in an all-cash deal for approximately $1.3 billion, adding RNA-targeting medicines to its pipeline.

Oct 19, 2026·3 sources
00
Oct 15, 2026

City Therapeutics raises $200 million in upsized US IPO for RNAi drugs

City Therapeutics Inc., an early-stage developer of RNAi-based drugs, raised $200 million in its US initial public offering, pricing shares at $18 at the midpoint of its marketed range. The biotech company is backed by Arch Venture Partners and Fidelity Management.

Oct 15, 2026·3 sources
00
Oct 14, 2026

Vir Biotechnology and Gilead partner on $1.88B cancer therapy deal

Vir Biotechnology signed a collaboration agreement worth up to $1.88 billion with Gilead Sciences to discover and develop T cell engager treatments for solid tumors, with Gilead paying $65 million upfront and $45 million in near-term milestones.

Oct 14, 2026·2 sources
00

Arrowhead Pharmaceuticals' ARO-MAPT shows first evidence of tau protein reduction in Alzheimer's trial

Arrowhead Pharmaceuticals reported interim Phase 1/2a results showing its experimental RNA interference drug ARO-MAPT successfully crossed the blood-brain barrier and reduced levels of tau protein, a key marker implicated in Alzheimer's disease. The subcutaneously administered treatment represents the first RNAi medicine to achieve this effect in the brain, with analysts describing the magnitude of tau reduction as compelling and potentially superior to other blood-brain barrier platforms.

Oct 14, 2026·4 sources
00
Oct 8, 2026

Endeavor BioMedicines' IPF drug meets Phase 2b primary endpoint

Endeavor BioMedicines announced that taladegib met the primary endpoint in a Phase 2b study for idiopathic pulmonary fibrosis, with the company claiming the drug has potential to reverse disease course rather than just slow progression.

Oct 8, 2026·2 sources
00

Roche partners with Defand Therapeutics in $1 billion degrader deal, fourth China partnership since August

Roche has signed a deal worth up to $1 billion with Hangzhou-based Defand Therapeutics to develop molecular glue degraders for oncology and immunology, with less than $10 million upfront. This marks Roche's fourth partnership with a Chinese biotech company in seven weeks.

Oct 8, 2026·2 sources
00
Oct 7, 2026

Henri B. Kagan and Kenso Soai win 2026 Nobel Prize in chemistry for mirror-image molecule research

Henri B. Kagan of Université Paris-Sud and Kenso Soai of Tokyo University of Science were awarded the 2026 Nobel Prize in Chemistry for discovering how to manipulate mirror-image molecules through asymmetric synthesis. Their work on nonlinear effects and autocatalysis has enabled the production of more precise and safer pharmaceuticals.

Oct 7, 2026·9 sources
00
Oct 5, 2026

Roche licenses Alector's Parkinson's disease therapy for up to $1.27 billion

Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, with $100 million upfront. The deal sent Alector's shares surging over 70% in premarket trading.

Oct 5, 2026·4 sources
00

Shionogi to acquire IntraBio for $2 billion

Japanese pharmaceutical company Shionogi has agreed to acquire American biotech IntraBio for $2 billion, gaining global rights to Aqneursa, a treatment for rare neurological conditions.

Oct 5, 2026·3 sources
00
Oct 3, 2026

Z-basivarsen shows sustained benefits in myotonic dystrophy type 1 trial

An investigational drug, z-basivarsen, demonstrated sustained improvements in myotonia, motor function, and strength in patients with myotonic dystrophy type 1, according to analysis from the ACHIEVE trial. The findings suggest potential therapeutic benefits for this genetic neuromuscular disorder.

Oct 3, 2026·2 sources
00
Sep 30, 2026

Eli Lilly's Foundayo demonstrates cardiovascular safety in ACHIEVE-4 diabetes trial

Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) met its primary cardiovascular safety endpoint in the Phase 3 ACHIEVE-4 trial, showing non-inferiority to insulin glargine in adults with type 2 diabetes and obesity. The study found a 16% lower risk of MACE-4 and 23% lower risk of MACE-3, though cardiovascular benefits remain unproven.

Sep 30, 2026·6 sources
00

Eli Lilly's amylin-Zepbound combination shows record 23% weight loss in diabetes trial

Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.

Sep 30, 2026·6 sources
00
Sep 27, 2026

Novo Nordisk shifts marketing of GLP-1 drugs from obesity 'patients' to lifestyle 'customers'

Novo Nordisk is increasingly positioning its GLP-1 medications as lifestyle drugs for 'customers' rather than obesity medicines for 'patients,' marking a significant shift in how the company markets these treatments. The change comes as the company continues developing next-generation weight loss drugs and expands its product pipeline.

Sep 27, 2026·4 sources
00
Sep 21, 2026

Imlunestrant combination approved for ESR1-mutated breast cancer

Eli Lilly's imlunestrant/abemaciclib combination has received approval for treating ESR1-mutated breast cancer. The key distinction from AstraZeneca's competing camizestrant/anti-CDK 4/6 therapy is the timing of endocrine therapy switching.

Sep 21, 2026·1 source
00

EMA committee recommends approval of glepaglutide for short-bowel syndrome

The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending Zeydovio (glepaglutide) for marketing authorization in treating short-bowel syndrome. The GLP-2 analog is developed by Zealand Pharma A/S.

Sep 21, 2026·1 source
00
Sep 20, 2026

Clinical trials face severe patient recruitment shortage across cancer and Alzheimer's disease

Clinical trials for major diseases are experiencing a critical shortage of participants, with only 7% of adult cancer patients in the U.S. enrolling in trials and Alzheimer's treatment studies facing similar global recruitment challenges despite new drug developments.

Sep 20, 2026·2 sources
00
Sep 17, 2026

Roche's Lunsumio meets primary endpoint in phase 3 follicular lymphoma trial

Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.

Sep 17, 2026·2 sources
00

Biotech hedge fund launches new immunology company

A biotech-focused hedge fund has established a new company focused on immunology research and development. The venture represents the fund's move into direct company creation in the biotechnology sector.

Sep 17, 2026·1 source
00

Experimental drug targets mesothelioma by disabling cancer's antioxidant defenses

Scientists are testing a new approach to fight mesothelioma by developing an experimental drug that kills cancer cells by disabling PRX3, an antioxidant defense mechanism that tumors use to survive oxidative stress. The counterintuitive treatment targets the aggressive asbestos-linked cancer, which currently has few effective treatment options.

Sep 17, 2026·1 source
00

Novo Nordisk signs up to $1.4B partnership with Orbis Medicines for cardiometabolic drugs

Novo Nordisk agreed to a partnership worth up to $1.4 billion with Lilly-backed Orbis Medicines to develop macrocycle pills for heart and metabolic diseases, marking Orbis' first major pharma deal.

Sep 17, 2026·2 sources
00
Sep 11, 2026

AstraZeneca's breast cancer pill fails late-stage trial after receiving FDA approval

AstraZeneca announced that its breast cancer pill failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial. The setback came just one week after the treatment received U.S. regulatory approval.

Sep 11, 2026·4 sources
00
Sep 2, 2026

Teva's celiac disease drug prevents intestinal damage in gluten challenge trial

Teva's experimental drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge in a mid-stage study, representing potential progress for a condition with no current drug treatments.

Sep 2, 2026·2 sources
00
Sep 1, 2026

Alumis experimental lupus drug fails primary endpoint in phase 3 trial

Alumis reported its experimental TYK2 inhibitor failed to meet the main goal of a late-stage lupus trial, though the company plans to advance the drug in a smaller subset of patients.

Sep 1, 2026·2 sources
00
Aug 31, 2026

Novartis and Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Novartis has halted development of rap-cel in multiple indications and Bristol Myers voluntarily paused enrollment in autoimmune CAR-T trials after observing safety issues in testing.

Aug 31, 2026·2 sources
00
Aug 28, 2026

BioNTech halts colorectal cancer vaccine trial after safety review finds treatment unlikely to extend survival

BioNTech ended a mid-stage study of its experimental mRNA cancer vaccine after an independent committee determined the treatment was unlikely to help colorectal cancer patients live longer.

Aug 28, 2026·2 sources
00
Aug 26, 2026

Biohaven licenses epilepsy drug platform to SK Biopharmaceuticals for up to $795 million

Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.

Aug 26, 2026·2 sources
00
Aug 18, 2026

Leo Pharma acquires worldwide rights to dersimelagon for up to $435M

Danish drugmaker Leo Pharma agreed to acquire worldwide rights to dersimelagon, a late-stage drug candidate for two rare genetic skin diseases, from Tanabe Pharma for up to $435 million in upfront and milestone payments.

Aug 18, 2026·2 sources
00
Aug 12, 2026

Boulevard Bio launches with $65M to develop targeted autoimmune antibody therapies

Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.

Aug 12, 2026·4 sources
00
Aug 10, 2026

Sionna Therapeutics halts cystic fibrosis drug development after trial failure

Sionna Therapeutics discontinued development of its experimental cystic fibrosis pill after it failed to show meaningful benefit when added to standard treatment in a mid-stage trial, causing shares to plunge.

Aug 10, 2026·2 sources
00

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to $1.32 Billion in Rare Epilepsy Deal

Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.

Aug 10, 2026·6 sources
00
Aug 6, 2026

Research identifies MDA-9 protein as potential drug target to overcome treatment resistance in head and neck cancer

New study shows that targeting the MDA-9 protein can restrain tumor growth and eliminate therapy resistance in head and neck squamous cell carcinoma, the seventh-most-common cancer type worldwide that is often diagnosed at late stages.

Aug 6, 2026·3 sources
00

Tarsus Pharmaceuticals to Acquire Alkeus for Up to $800M, Gaining Late-Stage Stargardt Disease Drug

Tarsus Pharmaceuticals agreed to acquire privately-held Alkeus Pharmaceuticals for $450 million upfront and up to $800 million total, gaining gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease. The rare genetic eye condition affects over 36,000 people in the U.S. and currently has no FDA-approved treatment, with pivotal trial data expected in late 2029.

Aug 6, 2026·5 sources
00
Aug 5, 2026

FDA approves Takeda's Orzeyful, first orexin agonist drug for narcolepsy type 1

The FDA has approved Takeda's Orzeyful (orexin agonist) for treating narcolepsy type 1 in adults, marking the first approval in a new class of sleep medicines that addresses the full range of narcolepsy symptoms. The approval is expected to reshape the treatment paradigm and launch a closely watched commercial drug race.

Aug 5, 2026·5 sources
00
Aug 4, 2026

Merck raises 2026 sales outlook on strength of newer drugs including Winrevair

Merck beat second-quarter estimates and boosted its 2026 sales forecast after strong demand for newer drugs like Winrevair helped drive revenues higher, though the company cut profit guidance due to deal-related charges.

Aug 4, 2026·2 sources
00
Jul 28, 2026

New research identifies Axl receptor blocking as potential treatment for osteoporosis

Scientists have discovered that blocking the Axl receptor may offer a novel approach to promoting bone formation, potentially providing a new treatment avenue for osteoporosis, a common age-related disease affecting millions worldwide.

Jul 28, 2026·1 source
00
Jul 26, 2026

Scientists revive vancomycin antibiotic by pairing it with second drug to overcome resistance

Researchers found a way to restore the effectiveness of vancomycin against resistant bacteria by combining it with another compound, rather than developing an entirely new antibiotic.

Jul 26, 2026·1 source
00
Jul 21, 2026

Gilead Sciences and Merck's Once-Weekly HIV Pill Maintains Viral Suppression in Phase 3 Trials

Gilead Sciences and Merck announced that their experimental once-weekly HIV pill combining islatravir and lenacapavir successfully maintained viral suppression at 48 weeks in two Phase 3 trials (ISLEND-1 and ISLEND-2) involving 1,209 adults with virologically suppressed HIV. The results support regulatory filings for what could become the first once-weekly oral HIV treatment regimen.

Jul 21, 2026·7 sources
00
Jul 16, 2026

Kalshi launches prediction markets for clinical trials and FDA drug approvals

Prediction market platform Kalshi will begin taking bets on the outcomes of clinical trials and FDA regulatory reviews, making drug-development odds public for the first time and expanding into biotechnology.

Jul 16, 2026·3 sources
00
Jul 9, 2026

ARPA-H Launches $160 Million Gene Editing Drug Development Program

The Advanced Research Projects Agency for Health (ARPA-H) has launched a $160 million initiative to fund seven groups over five years to develop custom gene editing drugs, aiming to replicate successes like the Baby KJ case.

Jul 9, 2026·1 source
00
Jun 29, 2026

Zymeworks Acquires Theravance Biopharma for $929 Million to Expand Beyond Cancer

Cancer-focused drugmaker Zymeworks will acquire Theravance Biopharma for $929 million in cash, marking its entry into the respiratory disease segment and expanding beyond its oncology focus.

Jun 29, 2026·2 sources
00
Jun 22, 2026

US Announces Clinical Trial Reforms to Accelerate Drug Research and Counter China Competition

The FDA and HHS are implementing sweeping reforms to speed up early-stage drug research in the United States, addressing concerns that pharmaceutical companies have increasingly moved clinical trials to countries like China and Australia. HHS Secretary Robert F. Kennedy Jr. announced the changes aimed at bringing investment back to the U.S.

Jun 22, 2026·2 sources
00
Jun 8, 2026

Zealand Pharma Shares Plunge 25% After Safety Data Raises Concerns Over Experimental Weight Loss Drug

Shares of Danish drugmaker Zealand Pharma dropped as much as 26% after new safety data on its experimental obesity medicine raised investor concerns over potential side effects.

Jun 8, 2026·1 source
00
May 28, 2026

GSK's Experimental Hepatitis B Drug Achieves Functional Cure in Nearly 1 in 5 Patients in Late-Stage Trials

GSK reported that its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, vastly outpacing current treatments and raising hopes for a finite treatment course as an alternative to lifelong therapy.

May 28, 2026·2 sources
00
May 27, 2026

Apogee Therapeutics Secures Up to $1.3 Billion from Blackstone for Eczema Drug Development

Apogee Therapeutics announced a financing deal with Blackstone Life Sciences worth up to $1.3 billion to support late-stage development and potential commercialization of its experimental eczema drug.

May 27, 2026·1 source
00
May 14, 2026

Biogen Advances Tau-Targeting Alzheimer's Drug to Phase 3 Despite Mixed Phase 2 Results

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies following a Phase 2 trial that showed mixed results.

May 14, 2026·1 source
00
May 13, 2026

Varda Space Industries Signs United Therapeutics as First Commercial Drug Manufacturing Customer

Varda Space Industries, a startup performing drug experiments in space, has signed pharmaceutical company United Therapeutics as its first commercial customer for orbital drug manufacturing.

May 13, 2026·1 source
00
May 12, 2026

Bristol Myers Squibb Partners with China's Hengrui Pharma on Dozen Drugs in $15.2B Deal

Bristol Myers Squibb and China's Hengrui Pharma announced a partnership to advance more than a dozen early-stage drugs in a deal worth up to $15.2 billion.

May 12, 2026·1 source
00
May 2, 2026

FDA Approves Merck's Idvynso, New Once-Daily Two-Drug HIV Treatment Tablet

The FDA has approved Merck's Idvynso (doravirine/islatravir), a once-daily, two-drug single tablet for treating HIV-1 infection in adults to replace current antiretroviral regimens in virologically suppressed patients.

May 2, 2026·1 source
00
Apr 17, 2026

Scientists Behind GLP-1 Obesity Drugs Propose Dropping GLP-1 as Target

Researchers who developed GLP-1 obesity medications are now advancing a provocative hypothesis that targeting the GLP-1 hormone may not be necessary for effective weight loss, potentially reshaping the approach to obesity treatment.

Apr 17, 2026·2 sources
00
Apr 16, 2026

New Anti-Clotting Drug Asundexian Reduces Stroke Risk Without Increased Bleeding

Large international trial found that investigational drug asundexian reduces stroke risk in people who recently experienced stroke or TIA without added bleeding complications.

Apr 16, 2026·1 source
00

Top claims

  • ▪Eli Lilly agreed to acquire Wellesley, Massachusetts-based biotech startup Calytrix Bio Inc. for up to $1.5 billion
  • ▪Eli Lilly has pursued company acquisitions throughout 2026 to expand into oncology, hematology, and autoimmune diseases beyond its blockbuster diabetes and weight-loss franchise
  • ▪Existing therapies for myeloproliferative neoplasms include blood transfusions and JAK inhibitor drugs such as Incyte's Jakafi, which manage disease symptoms rather than targeting underlying mutations

People involved

Michael SenaSam AltmanRobert F. Kennedy Jr.

Subtopics

Clinical trials41Drug Policy, Pricing & Approval33Drug Approval and Clinical Trials26Pharmaceutical Industry26Cancer & Oncology20Pharma18Cancer treatment12Autoimmune disease treatments10Rare diseases10Biotech innovation9Biotech startup9Mergers & acquisitions (M&A)9Cancer treatment breakthroughs8Clinical Trial Design & Evaluation8Oncology7Venture capital funding7Biomedical research6Eli Lilly6Biologic therapies5Biotechnology5Cancer immunotherapy5Cancer research5Clinical evaluation5Clinical trial endpoints5

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories